OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Neurology is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	548
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	346
Lymphatic propagation of α-synuclein	346
Brain stimulation aids walking after spinal injury	310
ANA2025 marks important milestones for the ANA and NINDS	258
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	256
Refining oxytocin therapy for autism: context is key	236
Reply to ‘Perils and pitfalls of near-death experience research’	233
Ventricular enlargement caused by aducanumab	228
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	226
Global synergistic actions to improve brain health for human development	220
Neural cell state shifts and fate loss in ageing and age-related diseases	213
Microglia, spreaders of Aβ seeds	209
NODDI reveals brain microstructural changes in multiple sclerosis	206
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	205
Disease-specific modifications of tau protein	183
Continuous levodopa production by an artificial enzyme	166
Imperatives and co-benefits of research into climate change and neurological disease	156
TREM2 mediates phagocytosis in glioblastoma	150
Study reveals new ALS risk genes	143
SEQUINS — a new initiative to address disparities in neurology	138
Nir Giladi (1955–2024)	134
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	132
Spinal muscular atrophy treatment in utero	132
The impact of rare genetic variants on Alzheimer disease	126

Mitochondrial DNA instability in Huntington disease	116
The Digitized Memory Clinic	112
The role of the gut microbiota in multiple sclerosis	110
Psychosis-causing lesions mapped to a hippocampal circuit	108
Neuroinflammation predicts cognitive decline in FTD	106
Ultrasound lets gene therapy into the brain	105
Implications of AD plasma and PET biomarker discordance	105
Menopause influences tau pathology	103
Role for endogenous retrovirus in FTD	102
Brain volume is associated with cognition in MS	94
Neurological care for LGBT+ people	91
Amyloid plaques: hotspots for microglial turnover	91
MRI-based deep learning for TLE diagnosis	89
Challenges of combining multimodal data in assessment of people with traumatic brain injury	89
Diversity, equity and inclusion in neurology	87
Brain imaging illuminates cognitive impairment in multiple sclerosis	84
Gene therapy for seizures in focal cortical dysplasia	83
Management of freezing of gait — mechanism-based practical recommendations	80
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	79
Author Correction: Viral pathogens increase risk of neurodegenerative disease	77
First trials test targeting of α-synuclein for Parkinson disease	75
Parkinson disease pathology can originate in the kidney	70
Precision neuroimmunology in multiple sclerosis — the horizon is near	70
APOE ε4 influences Parkinson disease progression	69
α-Synuclein pathology as a target in neurodegenerative diseases	68
The challenges of anti-tau therapeutics in Alzheimer disease	68
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	63
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	62
Food is brain medicine — relevance and translation to neurology	61
Evidence for altered astrocyte function in Duchenne muscular dystrophy	60
Glymphatic dysfunction in PD clinical progression	60
Neurosteroids alleviate seizures in rats	60
A new biological classification for Parkinson disease	59
Addressing disparities in neurology by building the workforce in LMICs	58